Ryan Potts - real

Ryan Potts - real

@pottslab.bsky.social

VP & Head of Induced Proximity Platform, @Amgen | Scientist | Father

1.3K followers1.1K following35 posts

Ryan Potts - real reposted

Science Magazine
@science.org

A new #ScienceReview looks at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.” Learn more: https://scim.ag/4lC2aCM

Ryan Potts - real
@pottslab.bsky.social

Check out how the Amgen Induced Proximity team repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @dnalawansha0509.bsky.social and team! #mycompany www.nature.com/articles/s41...

nature.comLYMTACs:chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization and degradationNature Communications - LYMTACs are heterobifunctional small molecules that take advantage of lysosomal membrane proteins to degrade membrane targets via relocalization and lysosomal degradation,...
Ryan Potts - real
@pottslab.bsky.social

🎓 Recent STEM grad? Jump-start your PhD journey with Amgen’s new 2-yr paid Postbaccalaureate Research Fellowship in Thousand Oaks! Work with world-class scientists, publish your findings, and make a real impact for patients. Apply by July 15 ➡️ amgen.wd1.myworkdayjobs.com/Careers/job/...

amgen.wd1.myworkdayjobs.comPostbaccalaureate Fellow - ResearchCareer Category Research Job Description Join Amgen’s Mission of Serving Patients At Amgen, if you feel like you’re part of something bigger, it’s because you are. Our shared mission—to serve patients...
Ryan Potts - real
@pottslab.bsky.social

We anticipate that unbiased phenotypic screening in combination with biased E3-focused small molecule libraries will continue to be a fruitful approach to molecular glue discovery. This amazing work comes from a large team at @amgen.bsky.social in collaboration w/ @PlexiumTx. Congrats to all

Ryan Potts - real
@pottslab.bsky.social

We extensively characterize the properties of dGEM3 to show biochemical reconstitution of the VHL:dGEM3:GEMIN3 ternary complex and ubiquitination consistent with a molecular glue without pre-existing affinity between VHL and GEMIN3. 5/7

Ryan Potts - real reposted

Sherry Pagoto, PhD
@drsherrypagoto.bsky.social

New report shows that NIH grants fueled $95 billion in economic activity and 407,782 jobs in 2024. That's not to mention the countless lives that biomedical research has saved. Show me a better investment than that. www.forbes.com/sites/michae...

forbes.comNIH Grants Fueled $95 Billion In FY 2024 Economic Activity, Finds New ReportNational Institutes of Health grants generated almost $95 billion in economic activity nationwide in FY 2024 according to a new report by United for Medical Research.
Ryan Potts - real
@pottslab.bsky.social

Overall, these results indicated that EN1441 is a pathfinding molecule that directly engages AR-v7 Cys125, leading to destabilization and aggregation and the subsequent inhibition of AR transcriptional activity and ultimately ubiquitin-mediated proteasomal degradation. 6/7

Ryan Potts - real
@pottslab.bsky.social

Further studies revealed that EN1441 inhibits AR-v7 transcriptional activity, leading to gene expression changes consistent with AR pathway inhibition. Importantly, this inhibition is more complete compared to therapies that only inhibit full-length AR and not AR-v7. 4/7

Ryan Potts - real
@pottslab.bsky.social

AR is a heavily drugged target in prostate cancer. A splice variant AR-v7 the occurs during the natural progression of disease has been challenging to drug. We performed a screen for AR-v7 degraders using a covalent fragment library leading to discovery of EN1441. 2/7

Ryan Potts - real reposted

Dan Nomura
@dannomura.bsky.social

Our latest BioRxiv by @cmzammit.bsky.social, Cory Nadel, @pottslab.bsky.social on a covalent destabilizing degrader against AR & AR-V7 in prostate cancer that targets an IDR C125 to destabilize, inhibit, and degrade TF! Thanks to @amgen.bsky.social, MTI, Berkeley MCB/Chemistry, NCI, TMFCR, and NSF!

biorxiv.orgCovalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer CellsAndrogen-independent prostate cancers, correlated with heightened aggressiveness and poor prognosis, are caused by mutations or deletions in the androgen receptor (AR) or expression of truncated varia...

Ryan Potts - real reposted

Sri Kosuri
@srikosuri.bsky.social

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS or other (non-LCH) dendritic or histiocytic sarcomas cases.

Ryan Potts - real
@pottslab.bsky.social

Somatic FBXW7-R465C mutant shows promise in targeted protein degradation in cancer cells. This approach enhances protein degradation specificity in diseased cells. Congrats Xiaoyu Zhang and colleagues. 🧪 #chembio #TPD #CancerResearch www.biorxiv.org/content/10.1...

biorxiv.orgHarnessing the FBXW7 somatic mutant R465C for targeted protein degradationTargeted protein degradation (TPD) is a pharmacological strategy that eliminates specific proteins from cells by harnessing cellular proteolytic degradation machinery. In proteasome-dependent TPD, exp...

Ryan Potts - real reposted

Bluesky
@bsky.app

Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪

Altmetric@altmetric.com

There are already many articles for which there is more attention on Bluesky than on other comparable micro-blogging sites, meaning the academic community and the general public have clearly adopted Bluesky as one of its core places to disseminate and discuss new research. A Place of Joy.

Ryan Potts - real reposted

Ingo Hartung
@hartungingo.bsky.social

There are no shortcuts in drug discovery. And it takes incredible efforts to make sense of what you can find in the scientific literature. This is an excellent piece of work to quality check what has been claimed as a new avenue in targeted protein degradation (TPD). www.nature.com/articles/s41...

nature.comCritical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets - Nature CommunicationsAutophagosome tethering compounds (ATTECs) are small molecule degraders hijacking the autophagy system. Here, the authors show that current ATTEC ligands did not bind to their designated targets but e...